retatrutide study news New weight-loss drug showing stronger results than current options Retatrutide produces up to 30.3%

During the median follow-up of 15.9 months, 137 major adverse cardiovascular events (MACEs) (61/1591 patients (3.8%) in the oral semaglutide group and 76/1592 patients (4.8%) in the placebo group) were documented [52]

Cai X, She M, Xu M, et al

While initial Phase 2 data demonstrated distinct metabolic effects from this concurrent activation [3], Retatrutide has since advanced into Phase 3 clinical evaluations including the TRIUMPH clinical program to further characterize its triple-agonist profile

Its a hormone released in the gut when you eat, and it has one job: make you feel full

doi: 10.1111/dom.13911

Notably, Novo Nordisk, a Danish pharmaceutical company, has recently developed the monoclonal antibody [MAb]3F52, which can specifically bind to the extracellular domain (ECD) Fab region of GLP-1R, and enabled the selective detection of GLP-1R in C57BL mice (43)